Dr. Bishoy Faltas, Assistant Professor of Medicine, Division of Hematology and Medical Oncology, has received a Starr Cancer Consortium (SCC) grant in support of his research study, entitled “APOBEC mutagenesis in bladder cancer: mechanisms and therapeutic opportunities.”
The Starr Cancer Consortium, established through a gift from The Starr Foundation, aims to advance research in new ways and impact the understanding, diagnosis, prevention, and treatment of cancer. The consortium is a collaborative framework that includes Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center, The Rockefeller University, The Broad Institute of MIT and Harvard and Cold Spring Harbor Laboratory.
After a rigorous review of numerous applications, Dr. Faltas’s study was selected by the SCC Executive Committee as part of the Twelfth Starr Cancer Consortium Grant Competition. The grant will provide $840,000 over two years.
“This generous support from the Starr Cancer Consortium will enable our team to investigate how APOBEC3-mutagenesis shapes the bladder cancer genome especially in critical forms of genomic instability such as chromothripsis. We hope to translate the knowledge we gain from our laboratory experiments into new therapies for bladder cancer patients,” says Dr. Faltas, who will serve as Principal Investigator for the study. The co-Principal Investigators are Dr. John Maciejowski, Ph.D., Memorial Sloan Kettering Cancer Center, and Dr. Eliezer M. Van Allen, M.D., The Broad Institute of MIT and Harvard.